Stock Track | Haemonetics Plummets 5.04% Intraday Following Series of Analyst Price Target Cuts
Stock Track
Feb 06
Haemonetics (HAE) stock experienced a sharp decline, plummeting 5.04% during intraday trading on Friday. The significant drop reflects heightened selling pressure on the healthcare company's shares.
The sell-off appears to be driven by a wave of analyst actions published earlier in the session. Citi lowered its price target on Haemonetics to $75 from $88, while maintaining a Neutral rating. Similarly, Mizuho Securities cut its target price to $80 from $90. Additionally, Baird reduced its price target to $81 from $99, though it kept an Outperform rating on the shares. These downward revisions in price targets from multiple firms likely contributed to negative investor sentiment and the stock's decline.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.